262 related articles for article (PubMed ID: 20521870)
1. Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain - an individual patient analysis.
Peniston JH; Xiang Q; Gould EM
Curr Med Res Opin; 2010 Aug; 26(8):1861-71. PubMed ID: 20521870
[TBL] [Abstract][Full Text] [Related]
2. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
Peniston JH; Gould E
Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
Hale ME; Dvergsten C; Gimbel J
J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
[TBL] [Abstract][Full Text] [Related]
4. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain.
Katz N; Rauck R; Ahdieh H; Ma T; Gerritsen van der Hoop R; Kerwin R; Podolsky G
Curr Med Res Opin; 2007 Jan; 23(1):117-28. PubMed ID: 17257473
[TBL] [Abstract][Full Text] [Related]
5. Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain.
Rauck R; Ma T; Kerwin R; Ahdieh H
Pain Med; 2008 Oct; 9(7):777-85. PubMed ID: 18950436
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
Hale ME; Ahdieh H; Ma T; Rauck R;
J Pain; 2007 Feb; 8(2):175-84. PubMed ID: 17145204
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of concomitant use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors and oxymorphone extended release.
Peniston JH; Hu X; Potts SL; Wieman MS; Turk DC
Postgrad Med; 2012 Mar; 124(2):114-22. PubMed ID: 22437221
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
9. Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.
Kopecky EA; Vaughn B; Lagasse S; O'Connor M
Drugs Aging; 2017 Aug; 34(8):603-613. PubMed ID: 28600725
[TBL] [Abstract][Full Text] [Related]
10. The pain quality response profile of oxymorphone extended release in the treatment of low back pain.
Gould EM; Jensen MP; Victor TW; Gammaitoni AR; White RE; Galer BS
Clin J Pain; 2009 Feb; 25(2):116-22. PubMed ID: 19333156
[TBL] [Abstract][Full Text] [Related]
11. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study.
Gabrail NY; Dvergsten C; Ahdieh H
Curr Med Res Opin; 2004 Jun; 20(6):911-8. PubMed ID: 15200750
[TBL] [Abstract][Full Text] [Related]
12. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study.
Rauck RL; Nalamachu S; Wild JE; Walker GS; Robinson CY; Davis CS; Farr SJ
Pain Med; 2014 Jun; 15(6):975-85. PubMed ID: 24517082
[TBL] [Abstract][Full Text] [Related]
13. Feasibility study of rapid opioid rotation and titration.
Korkmazsky M; Ghandehari J; Sanchez A; Lin HM; Pappagallo M
Pain Physician; 2011; 14(1):71-82. PubMed ID: 21267044
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study.
Sloan P; Slatkin N; Ahdieh H
Support Care Cancer; 2005 Jan; 13(1):57-65. PubMed ID: 15538638
[TBL] [Abstract][Full Text] [Related]
16. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
Matsumoto AK; Babul N; Ahdieh H
Pain Med; 2005; 6(5):357-66. PubMed ID: 16266356
[TBL] [Abstract][Full Text] [Related]
17. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes during opioid titration following initiation with or conversion to Remoxy®, an extended-release formulation of oxycodone.
Roland CL; Setnik B; Cleveland JM; Brown DA
Postgrad Med; 2011 Jul; 123(4):148-59. PubMed ID: 21680999
[TBL] [Abstract][Full Text] [Related]
19. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
20. Use of oral oxymorphone in the elderly.
Guay DR
Consult Pharm; 2007 May; 22(5):417-30. PubMed ID: 17658959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
